Pulmatrix EBITDA 2011-2026 | PULM

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Pulmatrix

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-9.66 M	-14.6 M	-18.8 M	-20 M	-9.65 K	-12.7 M	-20.1 M	-17.2 M	-17.1 M	-6.71 M	-3.12 M	-523 K	-30 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-9.65 K	-20.1 M	-10.8 M

Quarterly EBITDA Pulmatrix

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	806 K	-	-	-	-4.55 M	-	-4.98 M	-4.48 M	-4.93 M	-	-8.06 M	-3.76 M	-4.03 M	-	-1.12 M	-1.07 M	-4.69 M	-	-3.54 M	-7.85 M	-4.91 M	-5.11 M	-4.65 M	-6.01 M	-5.05 M	-	-4.12 M	-5.3 M	-3.25 M	-	-2.81 M	-8.85 M	-5.38 M	-	-4.48 M	-11.2 M	-2.68 M	-1.72 M	-2.35 M	-2.29 M	-	-658 K	-2.13 M	-1.47 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
806 K	-11.2 M	-4.14 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
Apellis Pharmaceuticals APLS	57 M	$ 20.36	-1.64 %	$ 2.57 B	USA
Aptorum Group Limited APM	1.19 M	$ 0.81	-3.83 %	$ 4.42 M	China
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Axsome Therapeutics AXSM	-166 M	$ 164.62	-1.06 %	$ 8.19 B	USA
AbCellera Biologics ABCL	-199 M	$ 3.74	-2.23 %	$ 1.12 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	242 M	$ 8.57	-1.95 %	$ 1.39 B	Britain
Certara CERT	96.2 M	$ 7.27	3.05 %	$ 1.17 B	USA
Catalyst Pharmaceuticals CPRX	258 M	$ 23.94	0.23 %	$ 2.93 B	USA
Corvus Pharmaceuticals CRVS	-23.3 M	$ 18.1	1.17 %	$ 869 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
Eton Pharmaceuticals ETON	-291 K	$ 17.89	-1.43 %	$ 459 M	USA
Exelixis EXEL	901 M	$ 40.99	-0.1 %	$ 11.1 B	USA
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	-23 M	$ 26.27	-2.2 %	$ 703 M	USA
Galapagos NV GLPG	-166 M	$ 33.2	-2.61 %	$ 2.69 B	Belgium
Greenwich LifeSciences GLSI	-16 M	$ 27.98	2.15 %	$ 364 M	USA
Galecto GLTO	-39.6 M	$ 29.63	-1.39 %	$ 787 M	Danmark
Genmab A/S GMAB	6.57 B	$ 27.76	-6.37 %	$ 17.6 B	Danmark
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	-53.6 M	$ 1.0	-1.47 %	$ 73.4 M	USA
Halozyme Therapeutics HALO	480 M	$ 69.4	-0.64 %	$ 8.32 B	USA
Hoth Therapeutics HOTH	-8.22 M	$ 1.01	-0.98 %	$ 6.44 M	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
Harmony Biosciences Holdings HRMY	232 M	$ 28.63	-0.95 %	$ 1.65 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
ImmuCell Corporation ICCC	1.03 M	$ 6.3	-3.67 %	$ 51.5 M	USA
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Immuron Limited IMRN	-2.87 M	$ 0.75	-0.69 %	$ 6.46 M	Australia
Immatics N.V. IMTX	-86.3 M	$ 9.95	-0.4 %	$ 626 M	Germany
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Immunic IMUX	-103 M	$ 1.12	5.19 %	$ 174 M	USA
Agenus AGEN	-146 M	$ 3.24	-3.14 %	$ 1.16 M	USA
Immunovant IMVT	377 K	$ 27.24	-1.84 %	$ 4.13 B	USA
Inhibrx INBX	-218 M	$ 76.35	-1.47 %	$ 3.6 B	USA
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
InMed Pharmaceuticals INM	-7.75 M	$ 0.78	-4.88 %	$ 1.91 M	Canada
INmune Bio INMB	-29.7 M	$ 1.39	4.66 %	$ 25 M	USA
Insmed Incorporated INSM	-1.24 B	$ 147.23	0.62 %	$ 29.3 B	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA